https://www.axios.com/pro/retail-deals/newsletters/2022/12/21/retail-thrifting-for-deals
Merck Announced KEYTRUDA Plus Padcev Reduced Risk of Death By More Than Half Versus Chemotherapy In Patients With Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-A39 trial (also known as EV-302), which was conducted in collaboration with Seagen and Astellas,
